Get started
Author

Anderson Clark

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
2012 · Angela Romanelli, Anderson Clark, et al. · Molecular Cancer Therapeutics · 49
PDF
Synthesis, evaluation, and metabolism of novel [6]-shogaol derivatives as potent Nrf2 activators
2016 · Yingdong Zhu, Pei Wang, et al. · Free Radical Biology and Medicine · 31
M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.
2016 · Andreas Machl, Erik W Wilker, et al. · PubMed Central · 31
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases
2021 · Manja Friese-Hamim, Anderson Clark, et al. · Lung Cancer · 27
The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
2023 · Joachim Albers, Manja Friese-Hamim, et al. · Molecular Cancer Therapeutics · 25
PDF
SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors
2013 · Srinivasa Karra, Yufang Xiao, et al. · Bioorganic & Medicinal Chemistry Letters · 17
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers
2021 · Lizbeth DeSelm, Bayard Huck, et al. · Journal of Medicinal Chemistry · 14
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab
2023 · Shota Fukuoka, Yoshikatsu Koga, et al. · Scientific Reports · 13
PDF
Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies
2023 · Samantha M. Goodstal, Jing Lin, et al. · Scientific Reports · 10
PDF
1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
2020 · S. Viteri, J. Mazieres, et al. · Annals of Oncology · 8
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors
2021 · Yufang Xiao, Bayard R. Huck, et al. · Bioorganic & Medicinal Chemistry Letters · 7
M7583 Is a Highly Selective and Potent Second Generation BTK Inhibitor for Treatment of B-Cell Malignancies
2017 · Samantha Goodstal, Jianguo Ma, et al. · Blood · 4
Pharmacodynamic (PD) biomarkers for the p70S6K/Akt inhibitor, M2698: Translation from animal to human and relevance to dose selection
2017 · W. Xiong, H. Tian, et al. · Annals of Oncology · 2
PDF
Abstract LB-456: Evaluation of brain pharmacokinetics as a potential differentiation factor for the MEK inhibitors, MSC2015103 and pimasertib
2012 · Jamie V. Shaw, Hong Zhang, et al. · Cancer Research · 2
Data from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
2023 · Joachim Albers, Manja Friese-Hamim, et al. · 1
MO01.46 Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC
2021 · S. Viteri, J. Mazieres, et al. · Journal of Thoracic Oncology · 1
PDF
Abstract 3407: Anti-tumor activity of tepotinib in orthotopic models of lung cancer patient-derived brain metastases with MET amplification
2020 · Manja Friese-Hamim, Anderson Clark, et al. · Cancer Research · 1
Abstract 139: M2698, a novel dual inhibitor of p70S6K and Akt: preclinical efficacy in gastric cancer
2017 · Shota Fukuoka, Takashi Kojima, et al. · Cancer Research · 1
Abstract 4516: Evaluation of p70S6K/Akt inhibitor MSC2363318A in patient derived xenograft (PDX) models of breast cancer
2014 · Bayard R. Huck, H Tian, et al. · Cancer Research · 1
Data from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
2023 · Joachim Albers, Manja Friese-Hamim, et al.
Table 1 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
2023 · Joachim Albers, Manja Friese-Hamim, et al.
Figure 2 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
2023 · Joachim Albers, Manja Friese-Hamim, et al.
Figure 2 from The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
2023 · Joachim Albers, Manja Friese-Hamim, et al.
Abstract 1146: Tepotinib treatment inhibits tumor growth and affects tumor permeability in an intracranial PDX model of MET-amplified NSCLC brain metastasis
2023 · Anderson Clark, Joachim Albers, et al. · Cancer Research
Data from Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts
2023 · Angela Romanelli, Anderson Clark, et al.
Works count: 36
Citation count: 245
H-index: 9
I10-index: 9
Year
Topic
Type